Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2020; 56(02): 112-115
DOI: 10.1055/s-0040-1713346
Brief Report

Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders

Skand Shekhar
1   Section on Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States
2   Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, United States
,
Caroline E. Copacino
3   Tufts University School of Medicine, Boston, Massachusetts, United States
,
Francisco J. Barrera
4   Endocrinology Division, Internal Medicine Department, University Hospital “Dr. Jose E. Gonzalez,” Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
5   Plataforma INVEST-KER Unit Mayo Clinic (KER Unit Mexico), School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
6   Knowledge and Evaluation Research, Mayo Clinic, Rochester, Minnesota, United States
,
Janet E. Hall
2   Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, United States
,
Fady Hannah-Shmouni
1   Section on Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States
› Author Affiliations Funding This work was funded by the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health (NIH).
› Further Information
   Permissions and Reprints

Abstract

Coronavirus disease 2019 (COVID-19) has affected millions of people across the world but disproportionately and severely affects persons with metabolic disorders such as obesity, diabetes mellitus, and hypertension. In this brief review, we discuss the pathways of immune dysregulation that may lead to severe COVID-19 in persons with metabolic conditions.

Keywords

COVID-19 - diabetes mellitus - hypertension - obesity


Publication History

Article published online:
24 June 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Organization WH. Coronavirus disease (COVID-2019) situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Published 2020. Updated April 30, 2020. Accessed May 1, 2020
  • 2 Garg S, Kim L, Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. Morb Mortal Wkly Rep 2020; 69 (15) 458-464
    CrossrefPubMedGoogle Scholar
  • 3 Lighter J, Phillips M, Hochman S. et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 2020; ciaa415
    PubMedGoogle Scholar
  • 4 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229) 1054-1062
    CrossrefPubMedGoogle Scholar
  • 5 Shekhar S, Wurth R, Kamilaris CDC, Eisenhofer G, Barrera FJ, Hajdenberg M, et al. Endocrine Conditions and COVID-19. Horm Metab Res. 2020
  • 6 Lan J, Ge J, Yu J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581 (7807) 215-220
    CrossrefPubMedGoogle Scholar
  • 7 Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368 (6490) 473-474
    CrossrefPubMedGoogle Scholar
  • 8 Wang N, Shi X, Jiang L. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23 (08) 986-993
    CrossrefPubMedGoogle Scholar
  • 9 Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity 2019; 50 (04) 1007-1023
    CrossrefPubMedGoogle Scholar
  • 10 Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017; 13 (04) 851-863
    CrossrefPubMedGoogle Scholar
  • 11 Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 2013; 14 (03) 232-244
    CrossrefPubMedGoogle Scholar
  • 12 Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009; 58 (11) 727-736
    CrossrefPubMedGoogle Scholar
  • 13 Luo X, Zhou W, Yan X. et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis 2020 ciaa641 DOI: 10.1093/cid/ciaa641.
    CrossrefPubMedGoogle Scholar
  • 14 Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40 (11) 1286-1292
    CrossrefPubMedGoogle Scholar
  • 15 Hundhausen C, Roth A, Whalen E. et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med 2016; 8 (356) 356ra119
    CrossrefPubMedGoogle Scholar
  • 16 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286 (03) 327-334
    CrossrefPubMedGoogle Scholar
  • 17 Luther JM, Gainer JV, Murphey LJ. et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48 (06) 1050-1057
    CrossrefPubMedGoogle Scholar
  • 18 Chamarthi B, Williams GH, Ricchiuti V. et al. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. Am J Hypertens 2011; 24 (10) 1143-1148
    CrossrefPubMedGoogle Scholar
  • 19 Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019; 4 (20) e131774
    CrossrefPubMedGoogle Scholar
  • 20 Stengel A, Goebel-Stengel M, Teuffel P. et al. Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 2014; 61: 75-82
    CrossrefPubMedGoogle Scholar
  • 21 Anoop S, Misra A, Bhatt SP, Gulati S, Pandey RM, Mahajan H. High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study. BMJ Open Diabetes Res Care 2017; 5 (01) e000393
    CrossrefPubMedGoogle Scholar
  • 22 Ryskjaer J, Deacon CF, Carr RD. et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155 (03) 485-493
    CrossrefPubMedGoogle Scholar
  • 23 Zhang J, Chen Q, Zhong J, Liu C, Zheng B, Gong Q. DPP-4 inhibitors as potential candidates for antihypertensive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs. Front Immunol 2019; 10: 1050-1050
    CrossrefPubMedGoogle Scholar
  • 24 Zhou F, Zhang Y, Chen J, Hu X, Xu Y. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2016; 791: 735-740
    CrossrefPubMedGoogle Scholar
  • 25 Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 2017; 18 (03) E563
    CrossrefPubMedGoogle Scholar
  • 26 Salem ESB, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306 (06) F629-F639
    CrossrefPubMedGoogle Scholar
  • 27 Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26 (3-4) 259-265
    CrossrefPubMedGoogle Scholar
  • 28 Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am 2001; 15 (02) 407-421
    CrossrefPubMedGoogle Scholar
  • 29 Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesity-related insulin resistance. Scand J Immunol 2019; 89 (04) e12747
    CrossrefPubMedGoogle Scholar
  • 30 Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res 2014; 59 (1-3) 243-253
    CrossrefPubMedGoogle Scholar
  • 31 Kvakan H, Luft FC, Muller DN. Role of the immune system in hypertensive target organ damage. Trends Cardiovasc Med 2009; 19 (07) 242-246
    CrossrefPubMedGoogle Scholar
  • 32 Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension 2012; 59 (04) 755-762
    CrossrefPubMedGoogle Scholar
  • 33 Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol 2014; 4 (03) 1177-1200
    CrossrefPubMedGoogle Scholar
  • 34 Meng J, Xiao G, Zhang J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9 (01) 757-760
    CrossrefPubMedGoogle Scholar
  • 35 Zhang P, Zhu L, Cai J. et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; DOI: 10.1161/CIRCRESAHA.120.317134.
    CrossrefPubMedGoogle Scholar
  • 36 Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2006923.
    CrossrefPubMedGoogle Scholar
  • 37 Reynolds HR, Adhikari S, Pulgarin C. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2008975.
    CrossrefPubMedGoogle Scholar